Start with COVID-19, then reuse UniProt P68400 as the stable protein anchor across project notes and exports.
CHEMBL3629 Target Snapshot
Casein kinase II subunit alpha · SINGLE PROTEIN · Homo sapiens
Research home keeps recent targets
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Switch target
Move to another high-traffic target or paste a specific ChEMBL target ID.
Frame the target before identity details
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Casein kinase II subunit alpha shows clinical signal disease relevance led by COVID-19. 4 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P68400. Start with COVID-19, then reuse UniProt P68400 as the stable protein anchor across project notes and exports.
Casein kinase II subunit alpha shows clinical signal disease relevance led by COVID-19. 4 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with COVID-19 because it currently carries clinical signal support. Linked drugs include SILMITASERTIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyCasein kinase II subunit alpha
Review this target as Casein kinase II subunit alpha, mapped to UniProt P68400. Sequence length is 391 aa.
Protein source · UniProt accession via ChEMBL component mappingCross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Casein kinase II subunit alpha as ChEMBL target CHEMBL3629, mapped to UniProt P68400. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Start with the right source
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Casein kinase II subunit alpha is the right protein anchor across sources, using UniProt P68400 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why COVID-19 is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardBasic Information
Verify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Casein kinase II subunit alpha |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P68400 |
Next Actions
UniProt Target Context
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Casein kinase II subunit alpha |
| UniProt Accession | P68400 |
| Component Type | Protein |
| Sequence Length | 391 aa |
Casein kinase II subunit alpha
How to read this target
Review this target as Casein kinase II subunit alpha, mapped to UniProt P68400. Sequence length is 391 aa.
Disease Relevance & Evidence Level
Open Targets-ready disease context using the current target-indication evidence contract.
Casein kinase II subunit alpha shows clinical signal disease relevance led by COVID-19. 4 more disease programs remain visible in the same review block.
How to read disease relevance
Start review with COVID-19 because it currently carries clinical signal support. Linked drugs include SILMITASERTIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Clinical Phase Distribution
Activity Type Distribution
Top Inhibitors (by pChEMBL)
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL4089961 | 10.89 | Kd | 0.01288 | Preclinical |
| CHEMBL4077554 | 10.5 | Kd | 0.03162 | Preclinical |
| CHEMBL3103191 | 10.32 | Kd | 0.0482 | Preclinical |
| CHEMBL4099729 | 10.03 | Kd | 0.09333 | Preclinical |
| CHEMBL3699289 | 9.89 | IC50 | 0.13 | Preclinical |
| CHEMBL3699277 | 9.85 | IC50 | 0.14 | Preclinical |
| CHEMBL3699234 | 9.82 | IC50 | 0.15 | Preclinical |
| CHEMBL3699295 | 9.8 | IC50 | 0.16 | Preclinical |
| CHEMBL4075338 | 9.79 | Kd | 0.1622 | Preclinical |
| CHEMBL3699235 | 9.77 | IC50 | 0.17 | Preclinical |
pChEMBL Value Distribution
Approved Drugs
Assay Landscape
Binding — 520 assays, 796 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 386 | 545 | 7.0 |
| assay format | 62 | 151 | 6.1 |
| cell-based format | 62 | 100 | 6.8 |
| subcellular format | 10 | 0 | — |
Functional — 144 assays, 209 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 143 | 1 | 5.8 |
| assay format | 1 | 208 | 6.1 |
ADME — 2 assays, 0 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 1 | 0 | — |
| cell-based format | 1 | 0 | — |